Your browser doesn't support javascript.
loading
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
Gaines, Hans; Albert, Jan; Axelsson, Maria; Berglund, Torsten; Gisslén, Magnus; Sönnerborg, Anders; Blaxhult, Anders; Bogdanovic, Gordana; Brytting, Maria; Carlander, Christina; Flamholc, Leo; Follin, Per; Haggar, Axana; Hagstam, Per; Johansson, Marcus; Navér, Lars; Persson Blom, Jenny; Samuelson, Agneta; Ström, Helena; Sundqvist, Martin; Svedhem Johansson, Veronica; Tegmark Wisell, Karin; Tegnell, Anders; Thorstensson, Rigmor.
Afiliação
  • Gaines H; a Public Health Agency of Sweden , Solna .
  • Albert J; b Unit of Infectious Diseases, Department of Medicine , Karolinska Institutet , Stockholm .
  • Axelsson M; c Department of Infectious Diseases , Karolinska University Hospital , Stockholm .
  • Berglund T; d Department of Microbiology , Tumor and Cell Biology, Karolinska Institutet , Stockholm .
  • Gisslén M; e Department of Clinical Microbiology , Karolinska University Hospital , Stockholm .
  • Sönnerborg A; f Swedish Reference Group for Antiviral Therapy , Stockholm .
  • Blaxhult A; a Public Health Agency of Sweden , Solna .
  • Bogdanovic G; a Public Health Agency of Sweden , Solna .
  • Brytting M; f Swedish Reference Group for Antiviral Therapy , Stockholm .
  • Carlander C; g Department of Infectious Diseases , Sahlgrenska Academy, University of Gothenburg , Gothenburg .
  • Flamholc L; c Department of Infectious Diseases , Karolinska University Hospital , Stockholm .
  • Follin P; e Department of Clinical Microbiology , Karolinska University Hospital , Stockholm .
  • Haggar A; f Swedish Reference Group for Antiviral Therapy , Stockholm .
  • Hagstam P; h Department of Laboratory Medicine, Division of Clinical Microbiology , Karolinska Institutet , Stockholm .
  • Johansson M; i Department of Infectious Diseases , Södersjukhuset Venhälsan , Stockholm .
  • Navér L; e Department of Clinical Microbiology , Karolinska University Hospital , Stockholm .
  • Persson Blom J; a Public Health Agency of Sweden , Solna .
  • Samuelson A; f Swedish Reference Group for Antiviral Therapy , Stockholm .
  • Ström H; j Clinic of Infectious Diseases, County Hospital of Västmanland , Västerås .
  • Sundqvist M; f Swedish Reference Group for Antiviral Therapy , Stockholm .
  • Svedhem Johansson V; k Department of Infectious Diseases , University of Lund, Skåne University Hospital , Malmö .
  • Tegmark Wisell K; l Department of Communicable Disease Control and Prevention , Region Västra Götaland , Gothenburg .
  • Tegnell A; m National Board of Health and Welfare , Stockholm .
  • Thorstensson R; n Department of Communicable Disease Control and Prevention , Skåne , Malmö .
Infect Dis (Lond) ; 48(2): 93-8, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26414596
ABSTRACT
In 2014 the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (RAV) conducted a review and analysis of the state of knowledge on the duration of follow-up after exposure to human immunodeficiency virus (HIV). Up until then a follow-up of 12 weeks after exposure had been recommended, but improved tests and new information on early diagnosis motivated a re-evaluation of the national recommendations by experts representing infectious diseases and microbiology, county medical officers, the RAV, the Public Health Agency, and other national authorities. Based on the current state of knowledge the Public Health Agency of Sweden and the RAV recommend, starting in April 2015, a follow-up period of 6 weeks after possible HIV-1 exposure, if HIV testing is performed using laboratory-based combination tests detecting both HIV antibody and antigen. If point-of-care rapid HIV tests are used, a follow-up period of 8 weeks is recommended, because currently available rapid tests have insufficient sensitivity for detection of HIV-1 antigen. A follow-up period of 12 weeks is recommended after a possible exposure for HIV-2, since presently used assays do not include HIV-2 antigens and only limited information is available on the development of HIV antibodies during early HIV-2 infection. If pre- or post-exposure prophylaxis is administered, the follow-up period is recommended to begin after completion of prophylaxis. Even if infection cannot be reliably excluded before the end of the recommended follow-up period, HIV testing should be performed at first contact for persons who seek such testing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes Sorológicos / Anticorpos Anti-HIV / Antígenos HIV / Infecções por HIV / Fármacos Anti-HIV / Profilaxia Pós-Exposição Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes Sorológicos / Anticorpos Anti-HIV / Antígenos HIV / Infecções por HIV / Fármacos Anti-HIV / Profilaxia Pós-Exposição Idioma: En Ano de publicação: 2016 Tipo de documento: Article